A na-atụ anya na ahịa injectors akpaaka ga-aga nke ọma na ijeri USD 5.74 na 2031

Gburugburu ụwa autoinjectors industry was valued at USD 1.52 ijeri in 2019. It is projected to reach USD 5.74 ijeri by 2031. This forecast period has a CAGR (or 18.2%) of 18.2%.

Ọchịchọ na-eto eto, The global auto-injectors market is also driven by rising self-medication, increasing demand for targeted drug delivery systems to treat chronic diseases, and government reimbursements.

However, the market is being held back by higher injector prices, a lack of self-injection practices in emerging nations, and the availability of substitute products.

Get a report sample to get a comprehensive insight @ https://market.us/report/auto-injectors-market/request-sample/

Ihe na-egbochi

According to product basis, autoinjectors are classified into fillable and prefilled injectors. The market was divided into disposable and reusable injectors according to their usability. This technology-driven growth sustains global growth in the autoinjectors industry. Drug side effects that can cause intolerance in humans are the most significant limiting factors to the autoinjectors market.

The United States is ranked sixth regarding leading causes of critical illness and allergy. In 2019, North America dominated the global auto-injectors market. Following manufacturing issues with Emerade’s auto-injector, Europe sees an increasing shortage of epinephrine. Critical companies can now focus on expanding their market presence.

Usoro igodo ahịa

Rheumatoid Arthritis is expected to have a significant market share over the forecast period.

Rheumatoid arthritis (RA) can be described as an autoimmune disease where the body’s immune systems attack the joints. It causes inflammation of synovium, swelling, pain, and swelling around the joints. Arthritis mostly affects the elderly. The prevalence of arthritis is higher in females than it is in males. According to United Nations World Population Prospects 2020, 727 million people over 65 are currently living in the world. This number is expected double by 2050. This is due to arthritis becoming more common in the geriatric population, increasing the segment’s growth over the forecast period.

Several recent studies show that most patients with rheumatoid arthritis who used an injector for treatment were more comfortable than those who received injections from someone else.

Market players also take the initiative to drive market growth. In March 2022, NORDIC PHARMA, a SEVER Health Sciences company, submitted a New Drug Submission (NDP) to Health Canada for Nordimet, a methotrexate autoinjector. It is used to treat severe disabling active rheumatoid arthritis (RA) and symptomatic control in adults with severe, recalcitrant psoriasis who are not responsive to other forms. The market is expected to grow if these drugs are approved.

Accordingly, this market segment will experience growth during the forecast period.

Mmepe nso nso a

• Antares Pharma (USA), and Lunatus Global Medical Supplies Dubai, signed an arrangement on August 2020. Antares is going to supply Lunatus packaged items. Lunatic is expected to submit and receive regulatory approvals for XYOSTED in the UAE and Saudi Arabia. They will also promote, market, and distribute XYOSTED.
• In March 2020, SHL Medical (Switzerland) acquired Weibel CDS (Switzerland). This acquisition allowed SHL Medical to offer a more advanced drug-delivery system that is human-centered and functional.
• US pharmaceutical giant Eli Lilly invested USD470 million in January 2020, creating more than 460 new jobs in Durham, NC. The expansion created a new pharmaceutical manufacturing facility at North Carolina’s research triangle park.
• Becton, Dickinson and Company, USA, introduced a disposable injector, BD Intevia1ml disposable self-injector, in November 2019. This will enable the company to increase its product line in autoinjectors.

Ụlọ ọrụ igodo

• Mylan
• BD
• Johnson na Johnson
• Ụlọ ọrụ Amgen Inc.
• Eli Lilly
• Biogen Idec
• Bayer
• Meridian (Pfizer)
• Ypsomed Holding
• Kaleo Inc.
• Owen Mumford
• Ụlọ ọrụ Antares Pharma Inc.
• Medeca Pharma AB

Akụkụ ahịa igodo

ụdị

• Disposable Auto-Injectors
• Reusable Auto-Injectors

ngwa

• Anaphylaxis
• multiple Sclerosis
• Rheumatoid Arthritiss

Ọtụtụ mgbe Ẹbụp Ajụjụ

• What are the key factors behind the rapid growth of the market for auto-injectors?
• What would be the CAGR in the auto-injector market during the forecast period
• What are the obstacles to growth in the auto-injector market?
• Which region has the best chance of securing more growth opportunities in the auto-injector market?
• Which major players are leading the auto-injector market
• How are company profiles chosen?
• What are the different segments of the auto-injector industry?
• Which segment of the auto-injector market captures the most significant share?

Akụkọ metụtara:

Global Autoinjectors Market Forecast To 2031 With Global Key Companies Profile Supply Demand And Cost Structure

Global Automotive Fuel Injectors Market Research 2022 Region Wise Analysis Of Top Players In Industry By Its Product Types And Application

Global Large Volume Wearable Injectors Market Production Sales And Consumption Status Report 2022-2031

Global Automatic Irrigation Equipment Market Sales Volume Sales Price Sales Revenue Analysis And Forecast To 2031

Global Automatic Lubrication System Market Specifications Production Growth Rate And Forecast By 2031

Banyere Market.us

Market.US (Kwadoro site na Prudour Private Limited) ọkachamara na nyocha na nyocha miri emi. Ụlọ ọrụ a na-egosipụta onwe ya dị ka onye na-eduzi ndụmọdụ na onye nyocha ahịa ahaziri iche na onye na-eweta akụkọ nyocha ahịa ahịa nke a na-akwanyere ùgwù nke ukwuu.

Nkọwa kọntaktị:

Otu mmepe azụmahịa zuru ụwa ọnụ - Market.us

Market.us (Kwuru site na Prudour Pvt. Ltd.)

Adreesị: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Ekwentị: +1 718 618 4351 (International), Ekwentị: +91 78878 22626 (Asia)

email: [email protected]